Veracyte annual gross margin
2011
2012
2013
2014
2015
2016
2017
2018
2019
2022
2023
2024
2025
Veracyte Gross Margin Growth & History (VCYT)
Veracyte's gross margin was 70.10% for fiscal 2025.
View full Veracyte company overviewVeracyte annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 70.10% | +3.22 pp |
| 2024 | 2024-12-31 | 66.88% | +3.27 pp |
| 2023 | 2023-12-31 | 63.62% | +4.37 pp |
| 2022 | 2022-12-31 | 59.24% | — |
| 2019 | 2019-12-31 | 70.03% | +5.98 pp |
| 2018 | 2018-12-31 | 64.05% | +3.23 pp |
| 2017 | 2017-12-31 | 60.81% | −0.06 pp |
| 2016 | 2016-12-31 | 60.88% | +4.30 pp |
| 2015 | 2015-12-31 | 56.57% | +0.06 pp |
| 2014 | 2014-12-31 | 56.52% | +14.13 pp |
| 2013 | 2013-12-31 | 42.39% | +7.61 pp |
| 2012 | 2012-12-31 | 34.78% | +45.36 pp |
| 2011 | 2011-12-31 | −10.59% | — |
Veracyte quarterly gross margin
Q3.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 72.21% | +3.25 pp |
| Q1 2026 | 2026-03-31 | 72.74% | +3.28 pp |
| Q4 2025 | 2025-12-31 | 72.51% | +6.12 pp |
| Q3 2025 | 2025-09-30 | 69.22% | +1.03 pp |
| Q2 2025 | 2025-06-30 | 68.97% | +0.88 pp |
| Q1 2025 | 2025-03-31 | 69.46% | +4.95 pp |
| Q4 2024 | 2024-12-31 | 66.39% | — |
| Q3 2024 | 2024-09-30 | 68.19% | +4.17 pp |
| Q2 2024 | 2024-06-30 | 68.09% | +6.29 pp |
| Q1 2024 | 2024-03-31 | 64.50% | — |
| Q3 2023 | 2023-09-30 | 64.02% | — |
| Q2 2023 | 2023-06-30 | 61.80% | — |
| Q4 2019 | 2019-12-31 | 67.46% | +1.27 pp |
| Q3 2019 | 2019-09-30 | 70.57% | +5.78 pp |
| Q2 2019 | 2019-06-30 | 70.88% | +7.12 pp |
| Q1 2019 | 2019-03-31 | 71.17% | +10.43 pp |
| Q4 2018 | 2018-12-31 | 66.20% | +5.84 pp |
| Q3 2018 | 2018-09-30 | 64.80% | +5.72 pp |
| Q2 2018 | 2018-06-30 | 63.76% | +1.57 pp |
| Q1 2018 | 2018-03-31 | 60.75% | −0.93 pp |
| Q4 2017 | 2017-12-31 | 60.35% | −3.96 pp |
| Q3 2017 | 2017-09-30 | 59.08% | −6.70 pp |
| Q2 2017 | 2017-06-30 | 62.19% | +5.12 pp |
| Q1 2017 | 2017-03-31 | 61.68% | +8.02 pp |
| Q4 2016 | 2016-12-31 | 64.32% | +8.28 pp |
| Q3 2016 | 2016-09-30 | 65.77% | +11.32 pp |
| Q2 2016 | 2016-06-30 | 57.06% | +0.22 pp |
| Q1 2016 | 2016-03-31 | 53.66% | −5.64 pp |
| Q4 2015 | 2015-12-31 | 56.03% | −4.09 pp |
| Q3 2015 | 2015-09-30 | 54.45% | −3.18 pp |
| Q2 2015 | 2015-06-30 | 56.84% | +2.55 pp |
| Q1 2015 | 2015-03-31 | 59.30% | +7.55 pp |
| Q4 2014 | 2014-12-31 | 60.12% | +10.88 pp |
| Q3 2014 | 2014-09-30 | 57.63% | +13.62 pp |
| Q2 2014 | 2014-06-30 | 54.29% | +18.05 pp |
| Q1 2014 | 2014-03-31 | 51.75% | +15.01 pp |
| Q4 2013 | 2013-12-31 | 49.24% | — |
| Q3 2013 | 2013-09-30 | 44.01% | +5.55 pp |
| Q2 2013 | 2013-06-30 | 36.25% | — |
| Q1 2013 | 2013-03-31 | 36.75% | — |
| Q3 2012 | 2012-09-30 | 38.46% | — |
Veracyte gross margin trends
Between the periods ended 2011-12-31 and 2025-12-31, Veracyte's gross margin increased from −10.59% to 70.10%, a change of +80.69 percentage points. The latest reported quarter, Q2 2026, shows 72.21%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Veracyte source filings ↗Community posts
New Decipher analysis links genomic scores to benefit from added hormone therapy
Veracyte ($VCYT) reported a retrospective analysis of samples from 395 participants in a randomized Phase III prostate-cancer trial. Patients with intermediate or high Decipher genomic scores had an eight-percentage-point reduction in ten-y ...
